TOKYO, JAPAN –\u00a0Media OutReach<\/a>
*1: Lactococcus
There is still no definitive cure or vaccine for dengue fever. However, the study results show there is hope for dealing with symptoms. The results of a clinical trial have confirmed the suppression of dengue fever-like symptoms through a food that is safe and does not rely on medical infrastructure, reflecting a groundbreaking achievement that has the potential to provide a solution to the global social issue of dengue fever. The results of this research were presented at the 25th Annual Meeting of the Japanese Society of Travel and Health<\/a> on August 22.<\/p>\n Since LC-Plasma activates the command
*2: Lactococcus
\u00a0<\/p>\n Kirin Holdings has reported that LC-Plasma
*3: Jounai et al., PLoS
*4: Sakata et al., Health<\/i> (2017)<\/a><\/p>\n [Attachments]\n 1.\t<\/span>Dengue Fever Joint Research Results Summary (1 page)<\/p>\n ATTACHMENT<\/u><\/b><\/p>\n \u00a0<\/p>\n DENGUE FEVER JOINT RESEARCH RESULTS SUMMARY<\/b><\/p>\n Clinical trial<\/b><\/p>\n According to the previous research
Figs. 1-3 Comparison of the cumulative number of days of
*5: Tsuji et al<\/i>., Antiviral Res<\/i> (2018)<\/a> \/ Suzuki et al<\/i>., Int J Mol Med.<\/i> (2019)<\/a><\/p>\n Outline of Collaborative Research<\/b><\/p>\n
\n– 17 September 2021 –\u00a0<\/b>A joint clinical
\ntrial confirmed that continuous intake of Kirin Holdings
\nCompany, Limited’s (Kirin Holdings) Lactococcus
\nlactis <\/i>strain Plasma (LC-Plasma)*1<\/sup> for two months significantly
\nreduced the cumulative number of days of fever, muscle pain, joint pain, and
\npain behind the eyes, which are known to be the main symptoms of dengue fever. LC-Plasma
\nis the same functional ingredient in Kirin Holdings’ stable of IMMUSE material that
\nhelp maintain the immune system. The study was conducted by The Kirin Central
\nResearch Institute in collaboration with Professor Dr. Sazaly Abu Bakar,
\nDirector of the Tropical Infectious Diseases Research & Education Centre
\n(TIDREC) at the University of Malaya. <\/p>\n
\nlactis<\/i> subsp. lactis<\/i> JCM 5805 is
\nowned by the RIKEN BioResource Research Center<\/a>.<\/p>\n\n
\nArises \u2013 In Food!<\/b><\/li>\n<\/ul>\n![](\"https:\/\/images.media-outreach.com\/Thumb\/500x0\/177647\/K1-en.JPG#image-177647\")
<\/p>\n
\ncenter of antiviral immunity, it has been shown to contribute to the prevention
\nof a wide range of viral infections other than the dengue fever virus*<\/a>2<\/sup>. Moving forward, Kirin Holdings and the University of Malaya will
\naccelerate joint research aiming to verify the antiviral effects of <\/i>LC-Plasma <\/i>on tropical disease viruses other than the dengue virus.<\/p>\n
\nlactis<\/i> strain Plasma Research Report https:\/\/health.kirin.co.jp\/ps\/index.html<\/a><\/p>\n
\nhas shown immunostimulatory effects in the body’s defense against viral
\ninfections through activation of plasmacytoid dendritic cells*3<\/sup> in non-clinical
\nand clinical trials, and that LC-Plasma can reduce the incidence of influenza*4<\/sup>
\nin clinical trials. In collaboration with TIDREC, a WHO Collaborating Centre for Arbovirus Reference
\nand Research<\/a>, our
\ncollaboration will continue to verify the effects of LC-Plasma on other tropical
\ninfectious diseases, which are expected to expand further due to global warming.
\nIn tandem, Kirin Holdings will make LC-Plasma more accessible to more people in
\nSoutheast Asia through alliances and business expansion, providing a solution
\nto a major social issue. <\/p>\n
\nOne<\/i> (2012) <\/a>\/ Sugimura et al., Clin. Immunol<\/i> (2013)<\/a><\/p>\n
\noutcomes performed by Kirin Holdings Company Limited*5<\/sup>, the Kirin
\nCentral Research Institute at Kirin Holdings Company Limited and the Tropical
\nInfectious Diseases Research and Education Center (TIDREC) at the University of
\nMalaya collaborated on a joint research project on Lactococcus lactis <\/i>strain Plasma (LC-Plasma) against dengue fever from
\nDecember 2019 to February 2020. During this time, approximately 100 healthy
\nadults of Malaysian nationality living in dengue infection cluster areas near
\nKuala Lumpur, Malaysia, were asked to take a tablet containing LC-Plasma (approximately
\n100 billion cells) or a placebo for 8 weeks, and symptoms were measured. The
\nresults showed that LC-Plasma significantly reduced the cumulative number of
\ndays with dengue fever-like symptoms such as headache, joint pain, and pain behind
\nthe eyes (Figures 1-3). These results suggest that LC-Plasma, a food product,
\ncan help alleviate the symptoms and prevent the severity of the disease, while
\nthe only other option currently available for dengue fever is coping therapy.<\/p>\n![](\"https:\/\/images.media-outreach.com\/Thumb\/500x0\/177654\/K3.JPG#image-177654\")
<\/p>\n
\noccurrence of symptoms specific to tropical diseases such as dengue fever\uff08Representative symptoms\uff09<\/p>\n\n
\nDisease Research and Education Centre (TIDREC), University of Malaya<\/li>\n
\nprofessor from Kirin Holdings Company, Limited.<\/li>\n
\nthe period will be extended as the project and research progress)<\/li>\n
\ninfectious diseases in order to , to contribute to public health in the region
\nand accelerate the overseas business development of Kirin Holdings’ health
\nscience business by:<\/li>\n<\/ul>\n–\u00a0\u00a0Confirmation of the efficacy of LC-Plasma against
\ntropical disease viruses (non-clinical research). Confirmation of the efficacy of LC-Plasma
\nagainst tropical
\ndisease virus infection \u00a0(clinical
\ntrials).<\/ul>\n–\u00a0\u00a0Confirmation of the efficacy of LC-Plasma
\nagainst tropical
\ndisease virus infection \u00a0(clinical
\ntrials).<\/ul>\n